Frontiers of Science: Aviv Regev
Aika
21.10.2021 klo 18.00 - 19.00
Frontiers of Science
October 21st at 18:00
Virtual event
Dr. Aviv Regev, Genentech Inc., US
Cell Atlases as roadmaps to treat disease
host: Riitta Lahesmaa (riitta.lahesmaa@utu.fi)
Register latest on October 20th at 12:00
https://link.webropolsurveys.com/S/FF9F82FD27003BD4
Students and early-career postdocs are welcome to share a virtual cup of coffee and discuss with Prof. Regev after the seminar. This is a great possibility to learn hosting skills in friendly environment and create connections for future. Every student are welcome to join, in spite of which research group they belong to.
If you got interested, after registering to the event please send an email to biocityturku@bioscience.fi
As utive Vice President, Genentech Research and Early Development (gRED), Aviv Regev is responsible for the management of all aspects of Genentech’s drug discovery and drug development activities. She is a member of the Genentech utive Committee and the expanded Corporate utive Committee for Roche.
Prior to Genentech, Regev served as Chair of the Faculty, Core Institute Member, founding director of the Klarman Cell Observatory, and member of the utive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas.
Regev is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease. Her lab has pioneered foundational experimental and computational methods in single-cell genomics, working toward greater understanding of the function of cells and tissues in health and disease, including autoimmune disease, inflammation and cancer. She is a member of the National Academy of Sciences and National Academy of Medicine, and she is also a Fellow of the International Society of Computational Biology.
Regev has served on multiple corporate advisory, scientific advisory, and journal editorial boards, including the advisory committee to the National Human Genome Research Institute at the National Institutes of Health. Regev has a Ph.D. in computational biology and a Master of Science from Tel Aviv University.
General information
•All autumn 2021 Frontiers of Science seminars are arranged online as eTALKs.
•Registration is obligatory and links to register are in BioCity Turku website (https://biocityturku.fi/) and advertised in our news feed.
•For Turku affiliated people it is now possible to register to all autumn 2021 seminars in one go.
•Registration closes and zoom link is sent to participants one day before the event.
•If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, please fill in your student number.
•If you wish to follow BioCity Turku news feed and receive up to date information about the Frontiers of Science seminars and other events, please contact biocityturku@bioscience.fi
October 21st at 18:00
Virtual event
Dr. Aviv Regev, Genentech Inc., US
Cell Atlases as roadmaps to treat disease
host: Riitta Lahesmaa (riitta.lahesmaa@utu.fi)
Register latest on October 20th at 12:00
https://link.webropolsurveys.com/S/FF9F82FD27003BD4
Students and early-career postdocs are welcome to share a virtual cup of coffee and discuss with Prof. Regev after the seminar. This is a great possibility to learn hosting skills in friendly environment and create connections for future. Every student are welcome to join, in spite of which research group they belong to.
If you got interested, after registering to the event please send an email to biocityturku@bioscience.fi
As utive Vice President, Genentech Research and Early Development (gRED), Aviv Regev is responsible for the management of all aspects of Genentech’s drug discovery and drug development activities. She is a member of the Genentech utive Committee and the expanded Corporate utive Committee for Roche.
Prior to Genentech, Regev served as Chair of the Faculty, Core Institute Member, founding director of the Klarman Cell Observatory, and member of the utive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas.
Regev is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease. Her lab has pioneered foundational experimental and computational methods in single-cell genomics, working toward greater understanding of the function of cells and tissues in health and disease, including autoimmune disease, inflammation and cancer. She is a member of the National Academy of Sciences and National Academy of Medicine, and she is also a Fellow of the International Society of Computational Biology.
Regev has served on multiple corporate advisory, scientific advisory, and journal editorial boards, including the advisory committee to the National Human Genome Research Institute at the National Institutes of Health. Regev has a Ph.D. in computational biology and a Master of Science from Tel Aviv University.
General information
•All autumn 2021 Frontiers of Science seminars are arranged online as eTALKs.
•Registration is obligatory and links to register are in BioCity Turku website (https://biocityturku.fi/) and advertised in our news feed.
•For Turku affiliated people it is now possible to register to all autumn 2021 seminars in one go.
•Registration closes and zoom link is sent to participants one day before the event.
•If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, please fill in your student number.
•If you wish to follow BioCity Turku news feed and receive up to date information about the Frontiers of Science seminars and other events, please contact biocityturku@bioscience.fi
Maija Lespinasse